Recursion insider plans sale of 100,000 shares
Recursion Pharmaceuticals, Inc. (symbol RXRX) reports a planned sale of 100,000 Class A shares through Fidelity Brokerage Services LLC on NASDAQ, dated August 13, 2026, at a listed value of $331,000.00.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Recursion Pharmaceuticals, Inc. (symbol RXRX) reports a planned sale of 100,000 Class A shares through Fidelity Brokerage Services LLC on NASDAQ, dated August 13, 2026, at a listed value of $331,000.00. These are identified as founders shares originally acquired on April 20, 2021 as compensation.
The notice also lists multiple Class A share transactions during the prior three months involving Christopher C. Gibson, Gibson Family Trust, and Lahwran-3 LLC, including individual transactions such as 340,440 shares for $1,089,541.29 on June 18, 2026 and several additional trades in July and August 2026.
Key Figures
Key Terms
compensation financial
Fidelity Brokerage Services LLC financial
Class A financial
Gibson Family Trust financial
Lahwran-3 Llc financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.